Published in Urology on September 16, 2009
Cryoimmunology for malignant bone and soft-tissue tumors. Int J Clin Oncol (2011) 0.91
Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study. J Immunother (2011) 0.84
Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer. Asian J Androl (2013) 0.78
The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. Rev Urol (2014) 0.77
Thermal ablation in cancer. Oncol Lett (2016) 0.75
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant (2008) 7.10
HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood (2012) 2.72
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39
High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood (2009) 2.25
Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 2.20
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant (2010) 2.17
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant (2008) 2.15
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant (2003) 1.81
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med (2013) 1.69
The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res (2004) 1.67
Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol (2012) 1.63
Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. J Urol (2012) 1.59
High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res (2010) 1.48
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest (2011) 1.46
Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology (2002) 1.44
Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant (2009) 1.41
Case of hereditary papillary renal cell carcinoma. J Community Hosp Intern Med Perspect (2012) 1.39
High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol (2010) 1.33
Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res (2006) 1.24
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant (2010) 1.18
Renal cell carcinoma seeding of a percutaneous biopsy tract. Can Urol Assoc J (2013) 1.17
Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant (2013) 1.13
Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology (2002) 1.10
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood (2002) 1.10
Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep (2011) 1.07
Renal tumor ablation. Tech Vasc Interv Radiol (2013) 1.06
Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. Fam Cancer (2008) 1.02
Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther (2006) 1.01
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant (2006) 0.99
Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res (2002) 0.97
Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett (2008) 0.97
Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol (2006) 0.97
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood (2007) 0.96
Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control (2002) 0.96
Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther (2009) 0.94
Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res (2006) 0.94
A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Res (2012) 0.93
Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Mol Ther (2007) 0.92
Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant (2013) 0.91
Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J Pharmacol Exp Ther (2006) 0.91
Safety and efficacy of CT-guided percutaneous cryoablation for renal cell carcinoma. J Vasc Interv Radiol (2008) 0.91
A novel method for generating and screening peptides and libraries displayed on adenovirus fiber. Nucleic Acids Res (2007) 0.90
Determinants of outcomes after resection of renal cell carcinoma with venous involvement. Int Urol Nephrol (2012) 0.90
Bone marrow transplantation for sickle cell anemia: progress and prospects. Pediatr Blood Cancer (2005) 0.90
Determination of the nonlethal margin inside the visible "ice-ball" during percutaneous cryoablation of renal tissue. Cardiovasc Intervent Radiol (2012) 0.89
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant (2003) 0.89
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant (2008) 0.89
Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector. Urol Oncol (2008) 0.88
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant (2007) 0.88
A real time Metridia luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the β-actin promoter and enhancer. PLoS One (2012) 0.88
A 66-year-old man with prostate-specific antigen recurrence and lung mass after radical prostatectomy. Urology (2012) 0.88
Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant (2013) 0.87
Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther (2004) 0.87
Preoperative diagnosis of malignant mesothelioma of the tunica vaginalis using Doppler ultrasound. Urology (2009) 0.87
Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Mol Cancer Ther (2004) 0.85
Complications of renal cryoablation: a single center experience. J Urol (2010) 0.85
Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotechnol (2012) 0.85
Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy. BJU Int (2014) 0.84
Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol (2015) 0.83
Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening. Cancer Res (2010) 0.82
Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J Pharmacol Exp Ther (2009) 0.82
Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell. Urol Int (2009) 0.82
Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas. Hum Pathol (2012) 0.81
Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Pract Res Clin Haematol (2011) 0.81
Evaluation of prostate-specific membrane antigen as an imaging reporter. J Nucl Med (2014) 0.80
Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol (2010) 0.80
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience. Br J Haematol (2002) 0.79
Single-center comparative oncologic outcomes of surgical and percutaneous cryoablation for treatment of renal tumors. J Endourol (2012) 0.79
Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. Curr Gene Ther (2012) 0.78
The role of lithium carbonate and lithium citrate in regulating urinary citrate level and preventing nephrolithiasis. Int J Biomed Sci (2009) 0.78
Renal function and oncologic outcomes after cryoablation or partial nephrectomy for tumors in solitary kidneys. Korean J Urol (2011) 0.78
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. J Comp Eff Res (2014) 0.77
Adenoviral gene therapy, radiation, and prostate cancer. Rev Urol (2005) 0.77
Does valproic acid induce neuroendocrine differentiation in prostate cancer? J Biomed Biotechnol (2010) 0.75
Allogeneic stem cell transplantation for sickle cell disease. Curr Opin Hematol (2016) 0.75
Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor. Nanomedicine (Lond) (2014) 0.75
Fat-predominant mixed epithelial stromal tumor (MEST): report of a unique case mimicking angiomyolipoma. Int J Surg Pathol (2008) 0.75
Incidental discovery of a renal cell carcinoma on native kidney biopsy. Am J Kidney Dis (2009) 0.75
Nonmyeloablative alternative donor transplants. Curr Opin Oncol (2003) 0.75
Lentivirus-mediated p21/Waf-1 short hairpin RNA enhances the cytotoxic effects and replicative potential of a bladder cancer-specific oncolytic adenovirus in vitro. Anticancer Drugs (2017) 0.75
Development of a research agenda for percutaneous renal tumor ablation: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol (2010) 0.75
Large renal metastasis from rare pulmonary neoplasm. Urology (2010) 0.75